Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy

Inclusion criteria

-Histologically or cytologically confirmed unresectable locally advanced NSCLC with progressed or recurred after no more than four previous docetaxel-free chemotherapy regimens, or unresectable locally advanced or metastatic SCCHN or recurred after previous docetaxel-free chemotherapy regimens

Exclusion criteria

• Women who are nursing or pregnant during the study period;
• Patients with carcinoid tumors, small-cell carcinoma of the lung;
• A history of another malignancy within the last five years (except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the uterine cervix);
• Any other morbidity or situation with contraindications for chemotherapy (e.g. active infection, myocardial infarction in the preceding 6 months);
• Neutrophil counts < 1,500 cells/mm3;
• A history of hypersensitivity to docetaxel or cisplatin;
• Symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias;
• Subjects have active hepatitis;
• Subjects are known positive for Human Immunodeficiency Virus (HIV);
• Any condition judged by investigator, participates the study will jeopardize patient's wellbeing